Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H, Sezer O, Dörken B, Gerecke C, Fuhrmann S, Ludwig WD, Hertenstein B, Bormann M, Meyer R, Naumann R, Platzbecker U, Röllig C, Rösler W, von Metzler I, Martin H, Engelhardt M, Finke J, Trümper L, Jung W, Schmidt CA, Dölken G, Wolf HH, Müller L, Ligeti K, Kröger N, Schilling G, Dürk H, Peest D, Ganser A, Pfreundschuh M, Sayer H, von Lilienfeld-Toal M, Mügge LO, Bentz M, Gramatzki M, Brüggemann M, Fischer T, Wolleschak D, Hess G, Kropff M, Reusch J, Straka C, Ostermann H, Franke D, Peschel C, Dechow T, Bassermann F, Hentrich M, Wandt H, Schäfer-Eckart K, Metzner B, Maschmeyer G, Holler E, Hart C, Reichle A, Freund M, Böttcher S, Kahl C, Mergenthaler HG, Aulitzky W, Kaufmann M, Greiner J, Heidemann E, Kanz L, Hebart H, Bunjes D, Langer C, Frickhofen N, Einsele H, Knop S, Mielke S, Bargou RC, Svaldi M (2019)

Publication Type: Journal article

Publication year: 2019

Journal

DOI: 10.1038/s41375-019-0537-2

Abstract

This phase 3 trial compared tandem autologous stem cell transplantation (autoSCT) versus autoSCT followed by reduced-intensity conditioning allogeneic stem cell transplantation (auto/alloSCT) in patients with newly diagnosed multiple myeloma (MM) with deletion of (del) chromosome 13q (del13q). The availability/absence of a human leukocyte antigen-matched-related or matched-unrelated donor (MUD) determined the nature of the second SCT. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population (n = 199). Auto/alloSCT was performed in 126 patients; 74 received MUD allografts. After 91 months median follow-up, median PFS with auto/allo versus tandem autoSCT was 34.5 versus 21.8 months (P = 0.003; adjusted hazard ratio 0.55, 95% confidence interval 0.36–0.84). Median overall survival (OS) was 70.2 versus 71.8 months (P = 0.856). Two-year non-relapse mortality with auto/allo versus tandem autoSCT was 14.3% versus 4.1% (P = 0.008). In patients harboring both del13q and del17p, median PFS and OS were 37.5 and 61.5 months with auto/allo (n = 19) versus 6.1 and 23.4 months with tandem autoSCT (n = 6) (P = 0.0002 and 0.032). Our findings suggest that auto/alloSCT significantly extends PFS versus tandem autoSCT in del13q MM, and indicate some survival benefit for first-line alloSCT in high-risk MM.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Regensburg Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Universitätsklinikum Tübingen Germany (DE) Carl von Ossietzky Universität Oldenburg Germany (DE) Technische Universität München (TUM) Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Universität Regensburg Germany (DE) Universitätsklinikum Jena Germany (DE) Otto-von-Guericke-Universität Magdeburg Germany (DE) Universitätsklinikum Halle (Saale) Germany (DE) Klinikverbund Bremen (Gesundheit Nord) Germany (DE) Klinikum rechts der Isar Germany (DE) Universitätsmedizin Rostock Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt) Germany (DE) Klinikum der Universität München Germany (DE) Universitätsklinikum des Saarlandes (UKS) Germany (DE) Universitätsklinikum Münster Germany (DE) St.-Johannes-Hospital Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Robert-Bosch-Krankenhaus Germany (DE) Klinikum Nürnberg Germany (DE) Universitätsklinikum Ulm Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Klinikum Ernst von Bergmann Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz Germany (DE) Universitätsklinikum Freiburg Germany (DE) Universitätsmedizin Greifswald / Universitätsklinikum Greifswald Germany (DE) St. Marien-Hospital Hamm Germany (DE) Universitätsklinikum Würzburg Germany (DE) Horst-Schmidt-Kliniken Germany (DE) Westfälische Wilhelms-Universität (WWU) Münster Germany (DE) Universität Rostock Germany (DE) HELIOS Kliniken Germany (DE) Klinikum Schwabing Germany (DE) Zentralkrankenhaus Bozen Italy (IT) Klinikum Stuttgart Germany (DE) Universitätsklinikum Göttingen Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE)

How to cite

APA:

Knop, S., Engelhardt, M., Liebisch, P., Meisner, C., Holler, E., Metzner, B.,... Svaldi, M. (2019). Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia. https://doi.org/10.1038/s41375-019-0537-2

MLA:

Knop, Stefan, et al. "Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis." Leukemia (2019).

BibTeX: Download